Last reviewed · How we verify
Cinarizine (CINNARIZINE)
Cinarizine (generic name: CINNARIZINE) is a cinnarizine drug. It is currently in Phase 2 development for Motion sickness, Nausea, Vertigo.
Cinarizine works by blocking histamine receptors in the brain, which helps to reduce symptoms of motion sickness and vertigo.
Cinarizine, also known as CINNARIZINE, is a small molecule drug that targets the histamine H1 receptor. It is used to treat motion sickness, nausea, and vertigo. The commercial status of Cinarizine is unknown, but it is likely off-patent. As a histamine H1 receptor antagonist, Cinarizine works by blocking the action of histamine, a chemical that can cause blood vessels to dilate and lead to symptoms of motion sickness and vertigo. This makes it easier for patients to manage their symptoms.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CINNARIZINE |
|---|---|
| Drug class | cinnarizine |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Imagine your brain is like a busy airport, and histamine is like a message that tells the 'air traffic control' to let more planes in. When you're on a boat or a car, your body gets confused and sends out too many of these messages, making you feel sick. Cinarizine is like a 'blocker' that stops these messages from getting through, helping you feel better.
Approved indications
- Motion sickness
- Nausea
- Vertigo
Common side effects
- Vestibular migraine
- Medication overuse headache
- Therapeutic response changed
- Endometrial cancer
- Bipolar disorder
- Portal tract inflammation
Key clinical trials
- Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo (PHASE4)
- Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism (NA)
- Therapeutic Effect of Quetiapine on Methamphetamine-Induced Psychosis (PHASE4)
- A Double-blind Comparison of Scopolamine With Cinnarizin for Prevention of Simulator Sickness (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cinarizine CI brief — competitive landscape report
- Cinarizine updates RSS · CI watch RSS
Frequently asked questions about Cinarizine
What is Cinarizine?
How does Cinarizine work?
What is Cinarizine used for?
What is the generic name of Cinarizine?
What drug class is Cinarizine in?
What development phase is Cinarizine in?
What are the side effects of Cinarizine?
What does Cinarizine target?
Related
- Drug class: All cinnarizine drugs
- Target: All drugs targeting Histamine H1 receptor
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Motion sickness
- Indication: Drugs for Nausea
- Indication: Drugs for Vertigo
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing